An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer and Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Excluding Predominant Squamous Cell Histology)

Trial Profile

An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer and Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Excluding Predominant Squamous Cell Histology)

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ARIES
  • Sponsors Genentech
  • Most Recent Events

    • 08 Jan 2016 Results of patients with non-small-cell lung cancer (n=1967) published in the Pharmacoepidemiology and Drug Safety
    • 02 Jun 2015 Results assessing post-progression survival of PointBreak, ARIES and ECOG 4599 trials presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 24 Jan 2013 Results from an analysis by gender will be presented at the 2013 ASCO Gastrointestinal Cancers Symposium according to a Sarah Cannon Research Institute media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top